PARTNERING & LICENSING

Partnering & Licensing, Thursday 1 March 2018

08:45

Organiser's Welcome Remarks

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng
09:00

Venture capital funding for the biotech industry

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important healthcare priorities, the role of the VC becomes even more crucial and necessary for early stage biotech company and its success. Find out how venture capitalists can tap on knowledge learnt from more established biotech ecosystem and apply these lessons in Asia. 
John Connolly
09:20

Fostering biotech and bio-entrepreneurship in Southeast Asia (SEA): How do we build the next biotech unicorn in SEA?

Southeast Asia is a geographically diverse region diverse lifestyles and traditions. The majority of SEA countries are still in developing stages and R&D intensive industries are not a priority compared to industries that rapidly close the income gap between the rich and the needy. Nonetheless, we are beginning to see a thriving biotech landscape offering innovative solutions. What needs to be done to help these promising companies fully realise their potential? How can the region come together to support the biotech industry, and build a biotech unicorn? 
Panel discussion
09:40

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?
 
Tabassum Khan, Managing Director, AJ Pharma Holding
10:20

Speed Networking

10:30

Exhibition Visit & Networking Refreshments

Partnering & Licensing
10:55

SOUTH ASIA

Join us at this interactive roundtable session for an informal, one hour discussion with local pharma companies interested licensing their products. Ideal for pharma companies looking for local partners and distributors, and for distributors looking for new business opportunities.
INDIA
  • Dinesh Kundu, Biologics Strategy and Project Manager, Intas Pharmaceutical, India
  • Kaustubh Berde, Vice President, Emerging Markets, Wockhardt, Indi
  • Sujay Singh, President & CEO, Imgenex India Pvt. Ltd, India
More attendees to be announced onsite
12:00

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 

Table 1: Innovative platforms for small molecules and gene therapy drug development

Table 2: Avoiding delays in clinical manufacturing of drug product

Manufacturing issues were the primary reason given for non-approvals in many of the response letters issued by the FDA in 2016. These manufacturing issues not only delay drug development, but also complicate the relationship between drug firms and their contract manufacturers. We will discuss the common issues, including planning, risk management, selection of primary packaging & materials, contract documents, and guidelines for choosing the right partner that can offer the quality necessary for successful clinical manufacturing. A trustworthy CDMO supports you with realistic project timelines and a framework of high product quality, while you focus on your core competencies of discovery and clinical development.

Table 3: Launching new biologics production line

Table 4: Commercial strategies for digital health in Asia

Amkidit Afable, Director Go-to-Market Strategies, Johnson & Johnson

Table 5: Why don’t we have an ICI in breast cancer – yet?

Table 6: Working on a start-up setting, from clinical development to commercialisation

Table 7: AI& Big data in drug discovery

Table 8: Preparation steps to brace healthcare & pharma digital transformation

12:50

Exhibition Visit & Networking Lunch

Partnering & Licensing
14:10

NORTH EAST ASIA

Join us at this interactive roundtable session for an informal, one hour discussion with local pharma companies interested licensing their products. Ideal for pharma companies looking for local partners and distributors, and for distributors looking for new business opportunities.
 
CHINA
  • Forrest Hu, General Manager, International Business, 3SBio, China
  • Ke Wu, CEO, BravoVax, China
  • H.Fai Poon, Chief Scientific Officer, Zhejiang Hisun Pharmaceuticals, China
  • Tim Collard, CEO, Pacific Gene Tech, China
  • Joe Zhou, CEO, Genor Biopharma, China
  • John Zeng, Executive Vice President, Shanghai Zerun Biotech, China
  • Tony Liu, CEO & CFO, Cellular Biomedicine, China
  • Lei Xiao, CSO and Chairman, Innovative Cellular Therapeutics (Formerly Sidansai Pharma), China
  • Gloria Wang, Executive Director, Clinical Development Just Biotherapeutics, China
  • Shuyuan Yao, Vice President, Operations, JW Therapeutics, China
JAPAN
AMED, Japan
Kenji Kakuta, President & CEO, iHeart Japan Corporation, Japan
 
KOREA
Antonio Lee, CEO & Managing Director, Medipost America, Global Head, Business Development, Medipost, South Korea
Jin-San Yoo, CEO, PharmAbcine, South Korea
Woong-Yang Park, Director, Samsung Genomic Institute, South Korea
Korean BioVenture Startup

More attendees to be announced onsite

 
15:20

Exhibition Visit & Networking Refreshments

Partnering & Licensing
16:00

SOUTH EAST ASIA


Join us at this interactive roundtable session for an informal, one hour discussion with local pharma companies interested licensing their products. Ideal for pharma companies looking for local partners and distributors, and for distributors looking for new business opportunities.
 
 
MALAYSIA & SINGAPORE
Tabassum Khan, Chairman, AJ Pharma, Malaysia
 
INDONESIA
Yuliana Indriati, President Director, PT Kalbe Genexine Biologics, Indonesia
 
THAILAND & VIETNAM
Wannarak Siraarparsate, Business Manager, Siam Bioscience, Thailand
 
Do Tuan Dat, General Director, Vaccine and Biological Production, Vabiotech, Vietnam
 
PHILIPPINES
Francis Wade Gomez, President and CEO, New Marketlink Pharmaceutical Corporation

More attendees to be announced onsite 
 
17:00

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 20/Feb/18 04:05

Partnering & Licensing, Friday 2 March 2018

09:00

Organiser's Welcome Remarks

09:05

Chair's Opening Remarks

Disruption & Digitalisation

Tony Liu
09:10

Shifting paradigm of the advanced therapy landscape in Asia

Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. From a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Upon approval for commercial deployment, what else needs to be done to help patients afford the sky high cost of immunotherapy? Join this thought provoking presentation to hear from Tony Liu, CEO of CBMG and former senior executive of Alibaba and Microsoft to learn how this influential biopharma company take steps to prepare for the next miracle drug in making. 
Antonio Lee
09:30

Innovation beyond limit: How do we conquer incurable diseases and create new history

Advancement in research helps to push the limitation of treatment paradigm to attempt curing currently incurable diseases. Innovative therapeutic solutions however is often not sufficient without a strong team to help with commercialisation. In this presentation, Antonio will share about the overall landscape in Asia stem cell therapy, challenges in current landscape and opportunities ahead to achieve commercial excellence.  
Ivor Lim
09:50

Educated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.
10:10

Exhibition Visit & Networking Refreshments

12:20

Exhibition Visit & Networking Lunch

13:20

Chair's Opening Remarks

Alfred Scheidegger
13:25

How to Capture Value in a Fast-Paced, Disruptive Industry

Bart Valdez
13:45

Global Growth of Outsourcing & Impact to Asia Markets

Bart Valdez, President, Strategic Resourcing, Syneos Health
Danny Yeung
14:05

Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma

Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.
 
Sebastian Sujka
14:25

AI in pharma: Using digital technology for disease prevention

14:45

Exhibition Visit & Networking Refreshments

Close of Phar-East 2018

last published: 20/Feb/18 04:05